Cargando…
The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer
The transmembrane protein, cMet, is thought to be overexpressed and activated in colorectal cancer (CRC). This study explored its potential as a diagnostic tissue biomarker for CRC in a large human CRC tissue collection obtained from a randomized clinical trial. Tissue microarrays of matched normal...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139376/ https://www.ncbi.nlm.nih.gov/pubmed/33951261 http://dx.doi.org/10.1111/iep.12395 |
_version_ | 1783695995186446336 |
---|---|
author | Armstrong, Gemma R. Khot, Mohammed Ibrahim Tiernan, Jim P. West, Nick P. Perry, Sarah L. Maisey, Tom I. Hughes, Thomas A. Jayne, David G. |
author_facet | Armstrong, Gemma R. Khot, Mohammed Ibrahim Tiernan, Jim P. West, Nick P. Perry, Sarah L. Maisey, Tom I. Hughes, Thomas A. Jayne, David G. |
author_sort | Armstrong, Gemma R. |
collection | PubMed |
description | The transmembrane protein, cMet, is thought to be overexpressed and activated in colorectal cancer (CRC). This study explored its potential as a diagnostic tissue biomarker for CRC in a large human CRC tissue collection obtained from a randomized clinical trial. Tissue microarrays of matched normal colorectal epithelium and primary cancer were prepared from specimens obtained from 280 patients recruited to the MRC CLASICC trial (ISRCTN 74883561) and interrogated using immunohistochemistry for cMet expression. The distribution and intensity of immunopositivity was graded using a validated, semiquantifiable score, and differences in median scores analysed using the Wilcoxon signedrank test. A receiver operating characteristic (ROC) curve was plotted to measure the diagnostic accuracy of cMet as a biomarker in CRC. Epithelial cell membrane expression of cMet differed significantly between CRC and normal colorectal tissue: median 12.00 (Interquartile range (IQR) 615) versus median 6.00 (IQR 2.7012.00) respectively (P=<.0001). ROCAUC analysis of cMet expression yielded a CRC diagnostic probability of 0.66 (95% CI: 0.61 to 0.70; P<.0001). A score of 14.50 showed high specificity at 85.32% (95% CI 80.33%89.45%) but sensitivity of only 30.92% (CI 25.37%36.90%). Thus cMet is consistently overexpressed in human CRC as compared to normal colorectal epithelium tissue. cMet expression may have a role in diagnosis and prognostication if combined with other biomarkers. |
format | Online Article Text |
id | pubmed-8139376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81393762021-05-24 The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer Armstrong, Gemma R. Khot, Mohammed Ibrahim Tiernan, Jim P. West, Nick P. Perry, Sarah L. Maisey, Tom I. Hughes, Thomas A. Jayne, David G. Int J Exp Pathol Original Articles The transmembrane protein, cMet, is thought to be overexpressed and activated in colorectal cancer (CRC). This study explored its potential as a diagnostic tissue biomarker for CRC in a large human CRC tissue collection obtained from a randomized clinical trial. Tissue microarrays of matched normal colorectal epithelium and primary cancer were prepared from specimens obtained from 280 patients recruited to the MRC CLASICC trial (ISRCTN 74883561) and interrogated using immunohistochemistry for cMet expression. The distribution and intensity of immunopositivity was graded using a validated, semiquantifiable score, and differences in median scores analysed using the Wilcoxon signedrank test. A receiver operating characteristic (ROC) curve was plotted to measure the diagnostic accuracy of cMet as a biomarker in CRC. Epithelial cell membrane expression of cMet differed significantly between CRC and normal colorectal tissue: median 12.00 (Interquartile range (IQR) 615) versus median 6.00 (IQR 2.7012.00) respectively (P=<.0001). ROCAUC analysis of cMet expression yielded a CRC diagnostic probability of 0.66 (95% CI: 0.61 to 0.70; P<.0001). A score of 14.50 showed high specificity at 85.32% (95% CI 80.33%89.45%) but sensitivity of only 30.92% (CI 25.37%36.90%). Thus cMet is consistently overexpressed in human CRC as compared to normal colorectal epithelium tissue. cMet expression may have a role in diagnosis and prognostication if combined with other biomarkers. John Wiley and Sons Inc. 2021-05-05 2021-06 /pmc/articles/PMC8139376/ /pubmed/33951261 http://dx.doi.org/10.1111/iep.12395 Text en 2021 The Authors. International Journal of Experimental Pathology published by John Wiley & Sons Ltd on behalf of Company of the International Journal of Experimental Pathology (CIJEP). https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Armstrong, Gemma R. Khot, Mohammed Ibrahim Tiernan, Jim P. West, Nick P. Perry, Sarah L. Maisey, Tom I. Hughes, Thomas A. Jayne, David G. The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer |
title | The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer |
title_full | The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer |
title_fullStr | The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer |
title_full_unstemmed | The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer |
title_short | The utility of cMet as a diagnostic tissue biomarker in primary colorectal cancer |
title_sort | utility of cmet as a diagnostic tissue biomarker in primary colorectal cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139376/ https://www.ncbi.nlm.nih.gov/pubmed/33951261 http://dx.doi.org/10.1111/iep.12395 |
work_keys_str_mv | AT armstronggemmar theutilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer AT khotmohammedibrahim theutilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer AT tiernanjimp theutilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer AT westnickp theutilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer AT perrysarahl theutilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer AT maiseytomi theutilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer AT hughesthomasa theutilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer AT jaynedavidg theutilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer AT armstronggemmar utilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer AT khotmohammedibrahim utilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer AT tiernanjimp utilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer AT westnickp utilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer AT perrysarahl utilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer AT maiseytomi utilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer AT hughesthomasa utilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer AT jaynedavidg utilityofcmetasadiagnostictissuebiomarkerinprimarycolorectalcancer |